MA26652A1 - Compositions pharmaceutiques mixtes pour le traitement de la faiblesse musculosquelettique, et procede pour leur preparation - Google Patents

Compositions pharmaceutiques mixtes pour le traitement de la faiblesse musculosquelettique, et procede pour leur preparation

Info

Publication number
MA26652A1
MA26652A1 MA25628A MA25628A MA26652A1 MA 26652 A1 MA26652 A1 MA 26652A1 MA 25628 A MA25628 A MA 25628A MA 25628 A MA25628 A MA 25628A MA 26652 A1 MA26652 A1 MA 26652A1
Authority
MA
Morocco
Prior art keywords
musculoskletal
weakness
preparation
treatment
pharmaceutical compositions
Prior art date
Application number
MA25628A
Other languages
English (en)
French (fr)
Inventor
Zhu Ke Hua
Li Mei
Codetta Pan Lydia
Duane Thompson David
Original Assignee
Pfizer Prod Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pfizer Prod Inc filed Critical Pfizer Prod Inc
Publication of MA26652A1 publication Critical patent/MA26652A1/fr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/02—Stomatological preparations, e.g. drugs for caries, aphtae, periodontitis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Physical Education & Sports Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Rheumatology (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
MA25628A 1998-06-16 1999-06-16 Compositions pharmaceutiques mixtes pour le traitement de la faiblesse musculosquelettique, et procede pour leur preparation MA26652A1 (fr)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US8946998P 1998-06-16 1998-06-16

Publications (1)

Publication Number Publication Date
MA26652A1 true MA26652A1 (fr) 2004-12-20

Family

ID=22217825

Family Applications (1)

Application Number Title Priority Date Filing Date
MA25628A MA26652A1 (fr) 1998-06-16 1999-06-16 Compositions pharmaceutiques mixtes pour le traitement de la faiblesse musculosquelettique, et procede pour leur preparation

Country Status (30)

Country Link
EP (1) EP1087764A1 (sk)
JP (1) JP2002518326A (sk)
KR (1) KR20010052852A (sk)
CN (1) CN1301160A (sk)
AP (1) AP9901582A0 (sk)
AR (1) AR018869A1 (sk)
AU (1) AU4054799A (sk)
BG (1) BG105041A (sk)
BR (1) BR9911324A (sk)
CA (1) CA2335134A1 (sk)
CO (1) CO5070587A1 (sk)
EA (1) EA200001186A1 (sk)
GT (1) GT199900087A (sk)
HN (1) HN1999000097A (sk)
HR (1) HRP20000859A2 (sk)
HU (1) HUP0102505A3 (sk)
ID (1) ID27599A (sk)
IL (1) IL138630A0 (sk)
IS (1) IS5691A (sk)
MA (1) MA26652A1 (sk)
NO (1) NO20006312L (sk)
OA (1) OA11505A (sk)
PA (1) PA8475901A1 (sk)
PE (1) PE20000646A1 (sk)
PL (1) PL344981A1 (sk)
SK (1) SK18912000A3 (sk)
TN (1) TNSN99124A1 (sk)
TR (1) TR200003544T2 (sk)
WO (1) WO1999065486A1 (sk)
ZA (1) ZA993975B (sk)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2360103A1 (en) * 1999-02-08 2000-08-17 Robert Sladek Non-human transgenic animal whose germ cells and somatic cells contain a knockout mutation in dna encoding orphan nuclear receptor erralpha
ATE346159T1 (de) 2000-05-08 2006-12-15 Pfizer Prod Inc Enzymatische spaltung von selektiven modulatoren des östrogenrezeptors
AU2001276608A1 (en) 2000-08-30 2002-03-13 Pfizer Products Inc. Sustained release formulations for growth hormone secretagogues
IL145106A0 (en) * 2000-08-30 2002-06-30 Pfizer Prod Inc Intermittent administration of a geowth hormone secretagogue
US7476653B2 (en) 2003-06-18 2009-01-13 Tranzyme Pharma, Inc. Macrocyclic modulators of the ghrelin receptor
WO2006024931A2 (en) * 2004-08-31 2006-03-09 Pfizer Products Inc. Therapeutic combinations comprising a selective estrogen receptor modulator and a selective androgen receptor modulator
CU23558A1 (es) 2006-02-28 2010-07-20 Ct Ingenieria Genetica Biotech Compuestos análogos a los secretagogos peptidicos de la hormona de crecimiento
BRPI0807046A2 (pt) 2007-02-09 2015-05-26 Tranzyme Pharma Inc Composto, composição farmacêutica, métodos de tratar um distúrbio, uma doença cardiovascular e um paciente que sofre de motilidade gastrointestinal reduzida ou disfuncional e, kit.

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
UA51676C2 (uk) * 1995-11-02 2002-12-16 Пфайзер Інк. (-)цис-6(s)-феніл-5(r)[4-(2-піролідин-1-ілетокси)феніл]-5,6,7,8-тетрагідронафталін-2-ол d-тартрат, спосіб його одержання, спосіб лікування захворювань, що піддаються лікуванню агоністами естрогену, та фармацевтична композиція
TW432073B (en) * 1995-12-28 2001-05-01 Pfizer Pyrazolopyridine compounds
HN1996000101A (es) * 1996-02-28 1997-06-26 Inc Pfizer Terapia combinada para la osteoporosis

Also Published As

Publication number Publication date
AR018869A1 (es) 2001-12-12
HUP0102505A2 (hu) 2001-11-28
IL138630A0 (en) 2001-10-31
OA11505A (en) 2004-05-07
NO20006312D0 (no) 2000-12-12
ID27599A (id) 2001-04-12
ZA993975B (en) 2000-12-15
HRP20000859A2 (en) 2001-04-30
HN1999000097A (es) 1999-11-03
AU4054799A (en) 2000-01-05
AP9901582A0 (en) 1999-06-30
TR200003544T2 (tr) 2001-04-20
SK18912000A3 (sk) 2001-10-08
PE20000646A1 (es) 2000-08-05
JP2002518326A (ja) 2002-06-25
HUP0102505A3 (en) 2002-12-28
BR9911324A (pt) 2001-04-03
GT199900087A (es) 2000-12-07
BG105041A (en) 2001-08-31
WO1999065486A1 (en) 1999-12-23
TNSN99124A1 (fr) 2005-11-10
PA8475901A1 (es) 2000-05-24
CO5070587A1 (es) 2001-08-28
KR20010052852A (ko) 2001-06-25
EA200001186A1 (ru) 2001-06-25
PL344981A1 (en) 2001-11-19
NO20006312L (no) 2000-12-12
IS5691A (is) 2000-10-27
CA2335134A1 (en) 1999-12-23
EP1087764A1 (en) 2001-04-04
CN1301160A (zh) 2001-06-27

Similar Documents

Publication Publication Date Title
MA26420A1 (fr) Compositions pharmaceutiques mixtes pour le traitement de l'osteoporose, et procede pour leur preparation.
FR2780057B1 (fr) Phenoxypropanolamines, procede pour leur preparation et compositions pharmaceutiques les contenant
MA26536A1 (fr) Association de compositions pharmaceutiques d'atorvastatine et d'agents antihypertensifs, et procede pour leur preparation.
MA26687A1 (fr) 4-carboxyamino-2-methyl-1,2,3,4-tetrahydroquinoleines, procede pour leur preparation et compositions pharmaceutiques les contenant
MA26654A1 (fr) Pyrrolopyrimidines nouvelles procede pour leur preparation et compositions pharmaceutiques les contenant
MA26622A1 (fr) Pyrazolopyrimidinones nouvelles, procede pour leur preparation et compositions pharmaceutiques les contenant
MA26433A1 (fr) Derives de pyridylpyrrole, procede pour leur preparation et compositions pharmaceutiques les contenant
MA26424A1 (fr) Derives de 6-phenylpyridyl-2-amine, procede pour leur preparation et compositions pharmaceutiques les contenant.
MA26508A1 (fr) Formulations pharmaceutiques contenant du variconazole, et procede pour leur preparation.
DZ2890A1 (fr) 4-Carboxamino-2-substitué-1,2,3,4-tétrahydroquinoléines, procédé pour leur préparation et compositions pharmaceutiques les contenant.
MA26630A1 (fr) 4-phenylpyperidines nouvelles, procede pour leur preparation et compositions pharmaceutiques les contenant
MA26465A1 (fr) Derives de quinoleine et derives de quinazoline nouveaux, procede pour leur preparation et compositions pharmaceutiques les contenant
MA26432A1 (fr) Derives de 2-(2-oxo-ethylidene)-imidazolidine-4-one, procede pour leur preparation et compositions pharmaceutiques les contenant.
MA26472A1 (fr) Derives de n-hydroxy-b-sulfonylpropionamide, procede pour leur preparation et compositions pharmaceutiques les contenant.
FR2748026B1 (fr) Nouveaux inhibiteurs de metalloproteases, leur procede de preparation et les compositions pharmaceutiques qui les contiennent
DZ2923A1 (fr) Formulations pharmaceutiques d'inhibiteurs de pde-5 de gmpc à libération contrôlée, et procédé pour leur préparation.
MA26468A1 (fr) Derives de sulfonyluree, procede pour leur preparation et compositions pharmaceutiques les contenant
MA26653A1 (fr) Pyrrolo [2,3- d] pyrimidines nouvelles, procede pour leur preparation et compositions pharmaceutiques les contenant
FR2722984B1 (fr) Procede de preparation de formes pharmaceutiques seches et les compositions pharmaceutiques ainsi realisees
MA26614A1 (fr) Bicyclo [2.2.1] heptanes nouveaux, procede pour leur preparation et compositions pharmaceutiques les contenant.
MA26559A1 (fr) Derives de d-proline, procede pour leur preparation, compositions pharmaceutiques les contenant et leur utilisation
MA26669A1 (fr) 1-aryl-3-arylmethyl-1,8-naphtyridine-4(1h)-ones nouvelles, procede pour leur preparation et compositions pharmaceutiques les contenant
DZ2600A1 (fr) Associations pharmaceutiques d'amlodipine et d'unestatine et procédé pour leur préparation.
MA26624A1 (fr) Derives de quinazolinamines nouveaux, procede pour leur preparation et compositions pharmaceutiques les contenant
FR2751334B1 (fr) Polysaccharides synthetiques, procede pour leur preparation et compositions pharmaceutiques les contenant